You are here: Home » Products » API » Tulathromycin
Product Search

Product Details

Share to:

Tulathromycin

Quantity:

Tulathromycin

CAS number: 217500-96-4

Molecular formula: C41H79N3O12

molecular weight: 806

Shelf Life: 2 years

Packing: 10kg/drum

Specification:

Test items

Enterprise specification

Test result

Character

White or off-white powder

White powder

Identification

A. The IR absorption spectrum of the

Substance to be examined corresponds to that of the reference standard.

B. The retention time of the principal peak in the chromatogram obtained with the test solution cooresponds to that of the principal peak in the chromatogram obtained with reference solution

A. Conform

B. Conform

Solubility

Insoluble in water, freely soluble in ethanol

Conform

Specific rotation

(anhydrous and solvents free)

-22º~-26º

-24º

Water

≤2.5%

2.0%

Related

substances

Any individual

unknown impurity

≤1.5%

0.15%

Total impurities

≤3.0%

0.99%

Residue on ignition

≤0.1%

0.07%

Heavy metal

≤20ppm

<20ppm

Bacterial Endotoxin

(Tulathromycin)

<2EU/mg

<2EU/mg

Residual

solvents

Methylene chloride

≤0.06%

Not detected

N-heptane

≤0.5%

0.003%

Assay

(anhydrous and solvents free)

The sum of tulathromycin A and tulathromycin B should be in the range of 95.0%~103.0%

101.4%

Purity

≥97.0%

99.0%

 

 

Functions of Tulathromycin 217500-96-4

 

•   Tulathromycin is a macrolide antibiotic used to treat bovine respiratory disease (BRD) in cattle and swine respiratory disease in pigs.

 

•   Clinical effectiveness of tulathromycin 217500-96-4, a novel triamilide antimicrobial, for the control of respiratory disease in cattle at high risk for developing bovine respiratory disease.

    The efficacy of tulathromycin 217500-96-4 in decreasing the incidence of morbidity and mortality due to bovine respiratory disease (BRD) in 1,239 high-risk cattle was investigated at four US feedlots. Calves not exhibiting clinical signs of BRD received one of three treatments administered subcutaneously in the neck: physiologic saline at 0.02 ml/kg, tulathromycin 217500-96-4 at 2.5 mg/kg, or tilmicosin at 10 mg/kg. Each treatment group consisted of 413 calves. Calves with clinical signs of BRD and rectal temperatures of 104 degrees F or higher on days 1 through 14 were considered treatment failures (BRD morbidity). Nasopharyngeal swabs from saline-treated morbidities were submitted for isolation and identification of BRD organisms. Respiratory disease morbidity was highest in calves treated with saline and significantly (P < or = .0001) lower in calves administered tulathromycin 217500-96-4 or tilmicosin. Morbidity from BRD was significantly (P < or = .0001) higher in calves treated with tilmicosin than in calves treated with tulathromycin 217500-96-4. Under conditions of this study, tulathromycin 217500-96-4, given to calves at high risk of developing BRD, was significantly more effective in reducing BRD morbidity when compared to both saline- and tilmicosin-treated calves.

 


Home

Add: Dinghao Square, No. 44, Gong Ye Nan Road, High-tech Zone, Jinan, Shandong Province, China    QQ: 121737357 /  2133109232   Skype: simonjh127  / bill.am@outlook.com 
Tel: +86-13145317722  +86-18254138679    Email: simon@anderchem.com / bill@anderchem.com
Copyright © 2019 Jinan Andechem Company Limited.  Sitemap. Support By Sdzhidian